Leinco Technologies

Anti-Mouse CD90.2 (Thy-1.2) - Purified in vivo PLATINUM™ Functional Grade

Product Code:
 
LEI-C430
Product Group:
 
Primary Antibodies
Host Type:
 
Rat
Antibody Isotype:
 
IgG2b κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
30-H12
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Applications:
  • Co-stimulation
  • Depletion
  • Flow Cytometry
  • Immunohistochemistry- Frozen Section (IHC-F)
  • In Vivo Assay
  • Mass Cytometry (CyTOF)
  • Western Blot (WB)
Shipping:
 
2-8°C
Storage:
 
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C430-1.0mg1.0 mg£283.00
Quantity:
LEI-C430-5.0mg5.0 mg£456.00
Quantity:
LEI-C430-25mg25 mg£1,335.00
Quantity:
LEI-C430-50mg50 mg£1,938.00
Quantity:
LEI-C430-100mg100 mg£2,741.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
CD90.2 is present on hematopoietic stem cells and neurons, all thymocytes, peripheral T cells of the Thy-1.2 bearing mice.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified in vivo Functional Grade, in vivo PLATINUM™
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Mouse thymus or spleen
Long Description:
CD90 is a 28-30 kD GPI-linked membrane glycoprotein and is part of the Ig superfamily. It interacts with CD45 in signal transduction. CD90 mediates adhesion of thymocytes to thymic stroma. It has been reported that CD90 binds with β2 and β3 integrins and is involved in the inhibition of hematopoietic stem cells proliferation and differentiation, as well as the regulation of cell adhesion and neurite outgrowth. It can be used as a marker for various stem cells, such as hematopoietic stem cells, and for the axonal processes of mature neurons. For use in FACS, CD90 is a popular surface marker for stem cells in combination with other markers such as CD34. There are two alleles for CD90 in mice that differ by one amino acid. The difference being that CD90.1 (Thy1.1) has an arginine and CD90.2 (Thy1.2) has a glutamine at position 108. CD90.2 is more prevalent and is expressed in most mice strains. CD90.1 is only expressed by a select few mice strains including AKR/J and PL strains. CD90.2 is a 25-35 kD GPI-anchored membrane glycoprotein. Like CD90, it is also in the Ig superfamily, interacts with CD45, and has involvement in signal transduction. The function of CD90.2 is thought to play roles in cognition, axon growth, T lymphocyte function, and apoptosis. CD90 acts as tumor suppressor for some tumors due to its action in upregulating thrombospondin, SPARC (osteonectin), and fibronectin. On the other hand, it has been suspected to aid in the spread of circulating melanoma cells. Regarding prostate cancer, CD90 has therapeutic potential for specific drug targeting due to its expression in cancer associated stroma, but not in normal stroma.
NCBI Gene:
21838
Purity:
?98% monomer by analytical SEC, >95% by SDS Page
Target:
CD90.2

References

1. Ledbetter, J. and Herzenberg, L. (1979) Immunol. Rev. 47:63 2. Unkeless, JC. (1979) J. Exp. Med. 150:580